Sofosbuvir / Velpatasvir / Voxilaprevir

Famotidine

Administration time adjustment is recommended.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Famotidine by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of velpatasvir .

Sofosbuvir / Velpatasvir / Voxilaprevir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Monitor for clinical efficacy.

Alternative solution(s)

Famotidine

Pharmacodynamic effects

Recommendations

Administrer at the same time and/or 12 hours after the combined drug.

Recommended dosage : dose not exceeding famotidine 40 mg twice daily or equivalent.

Alternative solution(s)

Monitor

Tests

Pharmacokinetic parameters
Parameters
Reference number
# patients
HCV
Dose
Frequency
AUC
Cmax
Sofosbuvir / Velpatasvir / Voxilaprevir
3379 3379
35 36
- -
400/100/100 mg 400/100/100 mg
x 1 x 1
- 6%/- 10%/- 2% † - 13%/- 15%/- 6% ††
- 4%/- 9%/- 10% † - 7%/- 13%/- 10% ††
Famotidine
3379 3379
35 36
- -
40 mg 40 mg
x 1 * x 1 **
   
   
Comment

Ref #3379 : * At the same time as sofosbuvir/velpatasvir/voxilaprevir;
† GS-331007 : AUC +4%; Cmax +8%;
** 12 hours after sofosbuvir/velpatasvir/voxilaprevir;
†† GS-331007 : AUC +1%; Cmax +14%.

Reference
  • 3379
    Sofosbuvir/Velpatasvir/Voxilaprevir (VOSEVI), Gilead, Ontario, Canada, 18 avril 2018.